ClinicalTrials.gg
RecruitingNCT07516067Updated Apr 7, 2026

Spinal Cord Stimulation for Children With Cerebral Palsy

An interventional study of Transcutaneous Spinal Cord Stimulation (tSCS) in Cerebral Palsy and Spasticity, sponsored by Martin Piazza. Recruiting at 1 site in United States. Open to participants aged 5 Years to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-07.

Sponsored by Martin Piazza · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
5 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 372 studies in Cerebral Palsy with a site in United States — 74 open to participants now, 102 under way, none of them phase 3. Cerebral Palsy · United States.

Planned enrollment
130th of 296
30 · median 25
Started
2026
with 23 others
No phase
218 of 372
49 open now
Primary completion
2026-11
later than 33 of 101 live
Registered
362nd of 372
by date

Among the 372 studies in Cerebral Palsy with a site in United States, this one is the 130th largest by planned enrollment of the 296 interventional ones that give a count, is one of 24 that started in 2026, is one of 218 with no phase, reaches primary completion later than 33 of the 101 other live ones, and was the 362nd registered.

Cerebral Palsy

1,942 studies on the registry are indexed under Cerebral Palsy; 456 are open to participants now.

Browse Cerebral Palsy studies →

Open to participants now

74 of the 372 studies in Cerebral Palsy with a site in United States are open now. Recruiting first, the newest first:

68 more — sign in →

All 74 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 271 Cerebral Palsy studies recruiting now, 26 (10%) set no upper age limit and 237 (87%) stop at 75 or younger; 256 take children under 18; 53 take healthy volunteers.

This study: 5 Years to 17 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 372 studies in Cerebral Palsy with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to help understand spinal cord excitability in children with cerebral palsy compared to neurologically typical children. The main questions it aims to answer are:

  • What are the mechanisms of spinal circuit hyperexcitability in CP?
  • Can transcutaneous spinal cord stimulation reduce spinal circuit hyperexcitability?

Participants with cerebral palsy will be asked to complete:

  • Movement and strength exercises
  • Mild, non-invasive stimulation on the back and legs that feels like a light tap.
  • Gentle, non-invasive tests that help us see how the brain and the spinal cord communicate with the muscles
Read the detailed description

This is a clinical trial designed to evaluate spinal circuit hyperexcitability in children with cerebral palsy (CP) and to explore the potential of transcutaneous spinal cord stimulation (tSCS) to reduce excitability and improve spasticity. The investigators will also examine the mechanisms underlying this potential reduction of spinal hyperexcitability.

The investigators will non-invasively record a range of electrophysiological responses using surface electrodes while participants perform isometric tasks. These recordings will help to better understand the differences in spinal excitability between children with CP and typically developing peers and will provide early insight into how tSCS might modulate these responses.

This study has two aims: The first aim is to evaluate spinal circuit excitability in Children with CP and in children without neurological conditions (controls). Several electrophysiological markers will be collected, including sensory reflex responses, reciprocal inhibition, motoneuron firing patterns, and motor evoked potential by transcranial magnetic stimulation. The second aim is to assess the impact of tSCS on spasticity and hypertonia in CP. To achieve this aim, the same electrophysiological measurements of spinal excitability will be repeated during non-invasive transcutaneous spinal cord stimulation in patient-participants (children with CP).

03

Conditions studied

  • Cerebral Palsy
  • Spasticity

Keywords

  • Cerebral Palsy
  • Spasticity
  • Spinal Cord Stimulation
  • tSCS
  • TMS
  • Transcutaneous Spinal Cord Stimulation
  • transcranial magnetic stimulation
04

Who can participate

Ages eligible
5 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A. Patient-Participant Group (Children with Cerebral Palsy)

  • Children aged 5 to 17 years with a confirmed diagnosis of cerebral palsy.
  • Gross Motor Function Classification System (GMFCS) Levels I to IV, able to walk with or without assistance (walker or cane). This classification will have been completed by Dr. Martin Piazza and his Movement Disorders clinic team.
  • Stable medical condition without recent surgeries or interventions that could affect motor function.
  • Must be able to communicate basic needs and follow simple instructions.
  • Provision of by a parent or legal guardian, with assent from the child as appropriate.

B. Control Group (Children without Neurological Diagnoses)

  • Children aged 5 to 17 years with no history of neurological diagnoses.
  • Must be fully ambulatory without assistance.
  • Must be able to communicate basic needs and follow simple instructions.
  • Provision of informed consent by a parent or legal guardian, with assent from the child as appropriate.

Exclusion criteria

Exclusion Criteria:

  • Presence of implanted medical devices (e.g., baclofen pumps, deep brain stimulators) that may interfere with TSCS.
  • Severe scoliosis or spinal deformities that could affect the delivery of tSCS.
  • Uncontrolled epilepsy or a history of frequent seizures.
  • Severe cognitive impairments limiting the ability to comply with study procedures.
  • Skin conditions or open wounds at the site of stimulation.
  • Participation in other interventional studies that may confound results.
  • Any serious disease or disorder (e.g. cancer, severe cardiac or respiratory disease, etc.) that could affect ability to participate in this study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • No intervention
    Control Group
  • Experimental
    Cerebral Palsy Group

    Transcutaneous spinal cord stimulation (tSCS) will be administered using the Digitimer DS8R Biphasic Constant Current Stimulator, an external isolated stimulator system used in human research. The DS8R delivers controlled electrical pulses with adjustable stimulation parameters. tSCS will be delivered at frequencies between 30-50 Hz with 1 ms pulse width and a biphasic waveform. Self-adhesive surface electrodes will be positioned longitudinally over the thoracolumbar region at T11-L1 (cathodes) and over the iliac crests (anodes). In children with cerebral palsy, electrophysiological and clinical assessments will be conducted before, during, and after stimulation to evaluate changes in spinal excitability, spasticity, and motor function. Stimulation is administered during supervised study visits.

    Device: Transcutaneous Spinal Cord Stimulation (tSCS)

Interventions

  • DeviceTranscutaneous Spinal Cord Stimulation (tSCS)

    Transcutaneous spinal cord stimulation (tSCS) will be administered using the Digitimer DS8R Biphasic Constant Current Stimulator, an external isolated stimulator system used in human research. The DS8R delivers controlled electrical pulses with adjustable stimulation parameters. tSCS will be delivered at frequencies between 30-50 Hz with 1 ms pulse width and a biphasic waveform. Self-adhesive surface electrodes will be positioned longitudinally over the thoracolumbar region at T11-L1 (cathodes) and over the iliac crests (anodes). In children with cerebral palsy, electrophysiological and clinical assessments will be conducted before, during, and after stimulation to evaluate changes in spinal excitability, spasticity, and motor function. Stimulation is administered during supervised study visits.

06

What researchers measure

Primary outcomes

  1. Change in H-reflex with Transcutaneous Spinal Cord Stimulation

    The primary outcome is H-reflex peak-to-peak amplitude with transcutaneous spinal cord stimulation (tSCS). Success criteria is measured as a reduction in 20 percent of peak-to-peak amplitude of the H-reflex.

    Time frame: Measured during 1 of up to 3 research sessions over up to 16 weeks

  2. Modified Ashworth Scale

    The primary outcome is the spasticity measured by the Modified Ashworth Scale with and without tSCS. The Modified Ashworth Scale is used to assess muscle spasticity. The scale is as follows: 0 = No increase in muscle tone; 1 = Slight increase in tone giving a catch when the limb is moved in flexion or extension; 1+ = Slight increase in muscle tone, indicated by a catch followed by minimal resistance throughout range of motion (ROM); 2 = More marked increase in tone through most of the ROM, but the limb easily flexed; 3 = Considerable increase in tone, passive movement difficult; 4 = Limb rigid in flexion or extension; Higher scores represent greater spasticity. Success criteria is measured as a reduction of at least 1 point in average across muscles. Scores will be averaged across assessed muscle groups to calculate a mean Modified Ashworth Scale score for each participant.

    Time frame: Measured during 1 of up to 3 research sessions over up to 16 weeks

Secondary outcomes

  1. TMS motor evoked potential

    A reduction in TMS motor evoked potential with tSCS is expected. Success criteria is measured as a decrease in 20 percent of the peak-to-peak amplitude with tSCS.

    Time frame: Measured during 1 of up to 3 research sessions over up to 16 weeks

  2. Reciprocal inhibition between antagonist muscles with tSCS

    Reciprocal inhibition will be tested by conditioning the H-reflex (elicited by stimulating at the tibial nerve) with a prior (between 1 and 5 ms) stimulation of the deep peroneal nerve. The results will be compared in CP vs control to determine its contribution in spinal hyperexcitability in CP. Additionally, the effect of tSCS in CP will be compared to determine whether tSCS can normalize hyperexcitability in CP. Success criteria is measured as a change in reciprocal inhibition of 20 percent towards the values in control participants.

    Time frame: Measured during 1 of up to 3 research sessions over up to 16 weeks

  3. Motoneuron excitability

    The investigators will measure the persistent inward currents of motoneurons as a measure of motoneuron excitability . A reduction in persistent inward current with tSCS is expected. The investigators will compare the results in CP vs control to determine its contribution in spinal hyperexcitability in CP. Additionally, the effect of tSCS in CP will be compared to determine whether tSCS can normalize hyperexcitability in CP. Success criteria is measured as a change in motoneuron excitability of 20 percent towards the values obtained in control participants.

    Time frame: Measured during 1 of up to 3 research sessions over up to 16 weeks

07

Study locations

1 of 1 sites recruiting
  • UPMC Children's Hospital of Pittsburgh
    Pittsburgh, Pennsylvania 15224, United States
    Recruiting
    • Bailey McDonald, BS · Contactmcdonaldbm3@upmc.edu · 412-692-9966
    • Martin G Piazza, MD · Contactpiazzamg@upmc.edu
    • Martin G Piazza, MD · Principal investigator
    • Genis Prat-Ortega, PhD · Sub investigator
    • Amit Sinha, MD · Sub investigator
    • George Wittenberg, MD, PhD · Sub investigator
    • Taylor Abel, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Nov 2026, 8 months after the start.

Of 906 non-industry interventional studies with no phase under Cerebral Palsy, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 31. This study's planned 8 months is below that.

Counting every sponsor, half of 925 studies reached it within 12 months; a quarter within 5 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2026
First posted
Apr 7, 2026
StartActual
Mar 30, 2026
Primary completionEst.
Nov 2026
CompletionEst.
Dec 2026
Last update
Apr 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07516067
Lead sponsor
Martin Piazza
Responsible party
Martin Piazza (Assistant Professor, Pediatric Neurosurgery, University of Pittsburgh) — Sponsor-investigator
First posted
Apr 7, 2026
Start date
Mar 30, 2026
Primary completion
Nov 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Apr 7, 2026

Study contacts

Bailey McDonald, BS
Contact
mcdonaldbm3@upmc.edu
412-692-9966
Martin G Piazza, MD
Contact
piazzamg@upmc.edu
Martin G Piazza, MD
principal investigator · University of Pittsburgh

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion